Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
18 February 2021 - 1:02AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of February 2021
Commission File Number: 001-39458
Medicenna Therapeutics Corp.
(Translation of registrant's name into English)
2 Bloor St. W., 7th Floor
Toronto, Ontario M4W 3E2, Canada
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ ] Form 40-F [ X ]
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): [ ]
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): [ ]
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
Medicenna Therapeutics Corp.
|
|
|
|
|
|
|
|
|
|
Date: February 17, 2021
|
By:
|
/s/ Elizabeth Williams
|
|
|
Name: Elizabeth Williams
|
|
|
Title: Chief Financial Officer
|
|
|
|
EXHIBIT INDEX
Medicenna Therapeutics (NASDAQ:MDNA)
Historical Stock Chart
From Apr 2024 to May 2024
Medicenna Therapeutics (NASDAQ:MDNA)
Historical Stock Chart
From May 2023 to May 2024